|
| Question | Almost never | Sometimes | Frequently | Almost always |
|
| Diagnosis and initial treatment |
| (1) Do you consider the metamorphopsia a red flag symptom? | 0% | 2% | 15% | 83% |
| (2) Do you consider a strong decrease of VA a key symptom of alert? | 0% | 1% | 22% | 77% |
| (3) Do you consider the appearance of a central scotoma a key symptom of alert? | 0% | 1% | 21% | 78% |
| (4) Do you consider a macular hemorrhage in a patient with drusen a key symptom of alert? | 0% | 1% | 5% | 94% |
| (5) Do you consider the macular edema in a patient with drusen a key symptom of alert? | 0% | 0% | 21% | 79% |
| (6) Do you consider the corrected VA an essential initial test? | 0% | 1% | 8% | 91% |
| (7) Do you consider the PPBMC an essential initial test? | 0% | 4% | 9% | 87% |
| (8) Do you consider the macular OCT an essential initial test? | 0% | 0% | 6% | 94% |
| (9) Do you consider the FA an essential initial test? | 0% | 18% | 42% | 40% |
| (10) Do you consider the loading doses (3 intravitreal injections) the routine way to begin treatment in all cases? | 2% | 7% | 21% | 70% |
| (11) Do you consider the initial loading dose feasible from a socio-sanitary point of view? | 5% | 15% | 46% | 34% |
| (12) Do you consider the PRN regimen (1 intravitreal injection + PRN) the routine way to start treatment in all the cases? | 35% | 40% | 18% | 7% |
| (13) Do you consider a complete series of diagnostic tests necessary during the loading phase? | 25% | 49% | 12% | 14% |
| (14) Do you consider a limited amount of diagnostic testing necessary during the loading phase? | 7% | 39% | 20% | 34% |
| (15) Do you consider monthly complete examinations in the PRN regimen feasible in NHS hospitals (Consider “complete examination” VA, OCT PPBMC)? | 35% | 48% | 15% | 2% |
| (16) Do you consider monthly complete examinations in the PRN regimen feasible in private hospitals (Consider “complete examination” VA, OCT PPBMC)? | 8% | 27% | 45% | 20% |
|
| Individualized treatment therapy |
| (17) Do you have in consideration the balance of risk/profit in deciding which guidelines to follow? | 1% | 6% | 57% | 36% |
| (18) Do you consider monthly treatment the most suitable regimen? | 16% | 21% | 40% | 23% |
| (19) Do you consider monthly treatment feasible in NHS hospitals? | 73% | 22% | 3% | 2% |
| (20) Do you consider monthly treatment feasible in public hospitals? | 30% | 37% | 28% | 5% |
| (21) Do you consider the PRN regimen with monthly visits the most suitable practice? | 2% | 25% | 51% | 22% |
| (22) Do you consider the PRN regimen with monthly visits feasible in NHS hospitals? | 32% | 36% | 30% | 2% |
| (23) Do you consider the PRN regimen with monthly visits feasible in private hospitals? | 8% | 24% | 60% | 8% |
| (24) Do you consider the T&E regimen the most suitable practice? | 3% | 53% | 38% | 6% |
| (25) Do you consider the T&E regimen feasible in NHS hospitals? | 8% | 38% | 52% | 2% |
| (26) Do you consider the T&E regimen feasible in private hospitals? | 5% | 25% | 58% | 12% |
| (27) Do you consider the W&E regimen the most suitable practice? | 12% | 56% | 31% | 1% |
| (28) Do you consider the W&E regimen feasible in NHS hospitals? | 2% | 26% | 67% | 5% |
| (29) Do you consider the W&E regimen feasible in private hospitals? | 4% | 19% | 69% | 8% |
| (30) Do you consider that, in general, most of the patients will be properly treated with seven injections during the first year of the treatment? | 0% | 10% | 80% | 10% |
| (31) Do you consider that, in general, most of the patients will be properly treated with four injections during the second year of the treatment? | 1% | 27% | 52% | 5% |
| (32) Do you consider it suitable to perform the intravitreal injection on the same day of the follow-up visit? | 3% | 23% | 22% | 52% |
| (33) Do you consider it feasible to perform the intravitreal injection on the same day of the follow-up visit in NHS hospitals? | 29% | 43% | 14% | 14% |
| (34) Do you consider it feasible to perform the intravitreal injection on the same day of the follow-up visit in private hospitals? | 5% | 24% | 42% | 29% |
| (35) Aside from the logistical factors, if you have a clean room in the consulting area, would you consider it appropriate to perform an intravitreal injection there? | 38% | 19% | 19% | 24% |
| (36) Do you consider performing the intravitreal injection in a clean room as safe as in the operating room? | 13% | 22% | 32% | 32% |
| (37) Do you consider it necessary that the retinal specialist perform himself VA check? | 25% | 42% | 20% | 13% |
| (38) Do you consider it necessary that the retinal specialist perform himself the OCT? | 15% | 32% | 27% | 26% |
| (39) Do you consider it necessary that the retinal specialist perform himself the FA? | 12% | 20% | 27% | 41% |
| (40) Do you consider it necessary that the retinal specialist perform by himself the PPBMC? | 2% | 16% | 24% | 58% |
|
| Nonresponders and referral to general ophthalmologist |
| (41) Do you consider an absolute nonresponder a patient with worsening VA and OCT macular thickness post-treatment? | 0% | 1% | 44% | 55% |
| (42) In the case of a nonresponder, should the checkup interval be reduced to 15 days since the last injection in order to test for a response? | 18% | 48% | 19% | 15% |
| (43) In the case of a nonresponder, should the AGF and ICG be repeated to rule out pathologies such as CP or RAP? | 0% | 13% | 28% | 59% |
| (44) Do you consider visual acuity less than 20/400 a criteria to refer the patient to the GO? | 13% | 59% | 22% | 6% |
| (45) Do you consider visual acuity less than 20/200 a criteria to refer the patient to the GO? | 42% | 49% | 6% | 3% |
| (46) Do you consider a fibrosis over 50% of the lesion (disciform scar) criteria to refer the patient to the GO? | 7% | 48% | 38% | 7% |
| (47) Do you consider the absence of retreatment criteria during the last 6 months a criterion to refer the patient to the GO? | 37% | 48% | 15% | 0% |
| (48) Do you consider the absence of retreatment criteria during the last 9 months a criterion to refer the patient to the GO? | 25% | 34% | 35% | 6% |
| (49) Do you consider the absence of retreatment criteria during the last 12 months a criterion to refer the patient to the GO? | 13% | 31% | 33% | 23% |
| (50) How many monthly injections do you usually perform to treat the relapses? | At least, a fixed load phase until the criteria of re-treatment disappeared
47% | Only until the criteria of retreatment disappeared
53% | | |
| (51) After how many injections do you define a nonresponder? | First injection
16% | After the loading phase
60% | After six months of treatment
20% | After first year of treatment
4% |
| (52) In the case of a nonresponder the second line treatment should be to | Interrupt the treatment with anti-VEGF
11% | Change the treatment with other anti-VEGF
42% | Use combined therapy
47% | Use the same treatment
0% |
|
